ARBs and target organ protection - Exploring benefits beyond their antihypertensive effects

作     者：Silverstein, RL Fenves, AZ Ram, CVS 

作者机构：Dallas Nephrol Associates Dallas TX USA Texas Blood Pressure Inst Dallas TX USA Univ Texas SW Med Ctr SW Med Sch Dallas TX USA Baylor Univ Med Ctr Dallas TX USA 

出 版 物：《POSTGRADUATE MEDICINE》 

年 卷 期：2004年第116卷第2期

页      面：31-+页

核心收录：

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 10[医学] 100602[医学-中西医结合临床] 

主　　题：Angiotensin-Converting Enzyme Inhibitors Blood Pressure Cardiovascular Diseases 血管紧张素转换酶抑制药 血压 心血管疾病 受体 血管紧张素 肾素-血管紧张素系统 antihypertensive activity Vital Signs REMEDIAL ACTION ASSESSMENT SYSTEM Cardiovascular Diseases Antihypertensive Agents target organ Angiotensin II Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors 

摘      要：Recognition of the role of the, renin-angiotensin-aldosterone system (RAAS) in initiating and maintaining hypertension prompted the development of drugs that disrupt the RAAS, notably the angiotensin converting enzyme (ACE) inhibitors and, more recently, the angiotensin II receptor blockers (ARBs). This article focuses on the use of ARBs in hypertension management and reviews evidence emerging from clinical trials that ARBs offer target organ protection over and above their antihypertensive activity.